NCT05886634

A Study of Etrumadenant and Zimberelimab in People With Dedifferentiated Liposarcoma

RecruitingPHASE2INTERVENTIONAL

Trial Details

Start: 2023-05-23Est. Completion: 2027-05-23

Enrollment target: 16 participants

Locations

Memorial Sloan Kettering at Basking Ridge (Limited Protocol Activities), Basking Ridge, New Jersey, United States
Memorial Sloan Kettering Monmouth (Limited Protocol Activities), Middletown, New Jersey, United States
Memorial Sloan Kettering Bergen (Limited Protocol Activities), Montvale, New Jersey, United States
Memorial Sloan Kettering Suffolk - Commack (Limited Protocol Activities), Commack, New York, United States
Memorial Sloan Kettering Westchester (Limited Protocol Activities), Harrison, New York, United States
Memorial Sloan Kettering Cancer Center, New York, New York, United States
Memorial Sloan Kettering Nassau (Limited protocol activities), Rockville Centre, New York, United States

Other microbiome trials you might be interested in

Measuring if Immunotherapy Plus Chemotherapy is Better Than Chemotherapy Alone for Patients With Aggressive Poorly Differentiated SarcomasPhase 3Recruiting

Metastatic Dedifferentiated LiposarcomaMetastatic Undifferentiated Pleomorphic SarcomaStage III Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8Stage IV Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8Unresectable Dedifferentiated LiposarcomaUnresectable Undifferentiated Pleomorphic Sarcoma

This phase III trial compares the effect of immunotherapy (pembrolizumab) plus chemotherapy (doxorubicin) to chemotherap…

Phoenix, United StatesEst. completion Apr 18, 2032

View Trial →

Natural History and Biospecimen Acquisition for Children and Adults With Rare Solid TumorsRecruiting

Malignant Solid Tumors

Apply or Learn More on ClinicalTrials.gov

MicrobiomeTrials does not provide medical advice. Always consult your doctor before joining a clinical trial.